profit from every $100 of sales.
$0$100
Journey Medical
$4.39-1.13% today
-51.7% in 1 year
1-year low $4.301-year high $9.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Journey Medical sold, what it kept, and what it did with the cash.
Sales went from $73.7 million in 2022 to $61.9 million in 2025, with -$11.4 million of profit last year.
SalesProfit
Journey Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Journey Medical | No profit yet | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Journey Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 74 | 79 | 56 | 62 | |
| 43 | 56 | 35 | 41 | |
| -28 | 1 | -18 | -8 | |
| -23 | 2 | -8 | -3 | |
| -30 | -4 | -15 | -11 | |
| -1.69 | -0.21 | -0.72 | -0.47 | |
| 58.2% | 71.1% | 62.8% | 66.2% | |
| -37.4% | 1.4% | -32.5% | -13.2% | |
| -40.2% | -4.9% | -26.1% | -18.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 105 | 77 | 80 | 95 |
| Cash | 32 | 27 | 20 | 24 |
| Total debt | 23 | 15 | 25 | 25 |
| Total liabilities | 88 | 56 | 60 | 63 |
| 17 | 20 | 20 | 32 | |
| 18 | 18 | 20 | 24 | |
| -54.5% | -4.4% | -20.8% | -10.6% | |
| -174.5% | -18.9% | -73.1% | -35.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14 | 5 | -9 | -12 | |
| 20 | 5 | 15 | – | |
| -34 | 0 | -24 | -12 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 3 | 6 | 6 |
Valuation
- –
- 60.6×
- –
- 5.5×
- 2.0×
- –
- –
- -10.0%
- -9.2%
- 0.0%
Profitability
- 66.2%
- -13.2%
- -18.5%
- -2.8%
- -11.3%
- -50.9%
- -35.6%
- -10.5%
- -11.8%
- 0.7%
Growth
- −5.7%
- –
- −36.3%
- –
- +9.1%
Financial health
- –
- 0.83
- 27.8%
- -1.7×
- 1.72
- 1.47
- 0.71
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 952
Bottom 14%of 883
Bottom 9%of 870
Bottom 11%of 985
What analysts expect
- Average price target
- $11.75
- Range
- $10.50 – $13.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.08 | -0.07 | −14.3% |
| Mar 25, 2026 | -0.04 | -0.06 | +33.3% |
| Nov 12, 2025 | -0.09 | -0.08 | −12.5% |
| Aug 12, 2025 | -0.16 | -0.07 | −128.6% |
| May 14, 2025 | -0.18 | -0.24 | +25.0% |
| Mar 26, 2025 | 0.08 | -0.22 | +136.4% |
| Nov 12, 2024 | -0.12 | -0.17 | +29.4% |
| Aug 12, 2024 | -0.17 | -0.15 | −13.3% |
News
Motivational speaker Mel Robbins’ real estate journey from a Massachusetts farmhouse to a Vermont retreatMarketWatch · Nov 3, 2026Soccer superstar Kylian Mbappé on ending 20-year journey with Nike: 'It was time to change'CNBC · Sep 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
24No pass
Philip Fisher
40No pass
Peter Lynch
21No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
38No pass
Questions about Journey Medical
Is Journey Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Journey Medical AI analysis
What does Journey Medical do?
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It is in Drug Manufacturers - Specialty & Generic.
Does Journey Medical pay a dividend?
No. Journey Medical does not pay a dividend at the moment.
Is Journey Medical stock halal?
Yes. Journey Medical passes our halal screen: its business is permitted and its debt is 20% of its market value, under the 30% limit. How we check
How has Journey Medical stock done over the past year?
Down 51.7% over the past twelve months, to $4.39. It traded between $4.30 and $9.26 and is 52.6% below its high.
Who are Journey Medical's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Journey Medical's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.